Hybrid peptides in the landscape of drug discovery

This publication has 13 references indexed in Scilit:

• Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease
  Cell, 2016
• Structure-based discovery of opioid analgesics with reduced side effects
  Nature, 2016
• A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
  Nature Medicine, 2014
• A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice
  Journal of Biological Chemistry, 2013
• Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
  Science Translational Medicine, 2013
• A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
  Biochemical Pharmacology, 2013
• Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
  Diabetes, 2013
• Targeted estrogen delivery reverses the metabolic syndrome
  Nature Medicine, 2012
• A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
  Nature Chemical Biology, 2009
• The fasting polypeptide FGF21 can enter brain from blood
  Peptides, 2007